T-Dxd

Advanced Solid Tumor

Daiichi Sankyoantibody_drug_conjugatePhase 1/2Active

CC

45/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 40/ 100
Competitive Position: 59/ 100

Competitive context

1411 Active assets in the Advanced Solid Tumor cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Inno-206 M.D. Anderson Cancer Center	Phase 2	BB
Vitamin B6 M.D. Anderson Cancer Center	Phase 4	BB
PROPOFOL Hong Kong Children's Hospital	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB

View all 50 →

Same molecule, other indications

T-Dxd is also rated in:

HER2 positive breast carcinomaDormant

B

Indicative ·

63 / 100

Breast NeoplasmsDormant

B

Indicative ·

56 / 100

metastatic malignant neoplasm in the brainDormant

CCC

Indicative ·

55 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.